• Subscribe
    • Sign up for updates about the journal.
  • Sign in
  • Register
Exploration of Targeted Anti-tumor Therapy
  • About
    • About the Journal
    • Editorial Board
    • Editorial Policies
    • Newsletter
    • Contact Us
  • Articles
    • Current Issue
    • Archives
  • Special Issue
    • All Special Issues
    • Guest Editor Guidelines
  • For Authors
    • Author Instructions
    • Editorial Process
    • Article Processing Charge
    • Submit a Manuscript
  • For Reviewers
    • Peer Review Guidelines
    • Reviewer Acknowledgment
    • To Be a Reviewer
  • Focus
  • Home
  • Exploration of Targeted Anti-tumor Therapy
  • Special Issues
  • Special Issue Topic

    Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment

    Submission Deadline: January 20, 2023

    Guest Editor

    Dr. Arun Seth E-Mail

    Scientific Director of Molecular Diagnostics, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre; Academic Director, Genomics Core Facility, Senior Scientist, Sunnybrook Research Institute; Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada

    Research Keywords: precision oncology; breast and prostate cancer biology; molecular diagnostics; genomic profiling; next-generation sequencing; targeted cancer therapy


    About the Special Issue

    Biomarkers are biological molecules that can be evaluated as an indicator of a normal biological and pathogenic process, or a pharmacologic response to a drug. Identification of key cancer biomarkers is crucial for diagnosis, prognosis, treatment, and therapeutic responses. A wide range of technologies have been used to study and discover biomarkers including mass spectrometry, imaging, next generation sequencing.
    Cancer is a complex disease and develops due to the accumulation of genetic and epigenetic alterations. Precision cancer medicine promotes treatment options based on a patient's profile of genetic variations. This requires validated predictive and prognostic biomarkers that can guide the clinical management of individual cancer patients. The focus in precision and personalized cancer medicine is to identify effective approaches for patients based on genetic factors. Most tumors harbor genetic mutations unique to each patient’s cancer. A subset of these mutations drive oncogenesis by conferring a selective growth advantage to the tumor cell. Many cancers specific changes are druggable with highly specific anticancer agents such as small molecules or monoclonal antibodies. In certain cancer cases, companion diagnostic tests are used to identify safe and effective use of a corresponding targeted therapeutic. Precisely targeted mutated proteins can specifically inhibit cancerous cell growth and achieve remission with fewer side effects than traditional chemotherapies.

    Keywords: Biomarkers; precision oncology; molecular diagnostics; companion diagnostics; patient profiling; personalized medicine; targeted therapy; genomics; transcriptomics; proteomics; metabolomics; imaging

    Call for Papers

    Published Articles

    Open Access
    Case Report
    Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
    A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral [...] Read more.

    A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma rat sarcoma viral oncogene homolog (NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type, proficient mismatch repair (pMMR), in whom a complete response to the third-line of systemic treatment with trifluridine/tipiracil (TAS-102) was obtained. The complete response has been maintained for more than 2 years after its suspension.

    Celia Lara-Morga ... Luis Cabezón-Gutiérrez
    Published: April 27, 2023 Explor Target Antitumor Ther. 2023;4:307–315
    DOI: https://doi.org/10.37349/etat.2023.00136
    Full Text
    PDF
    View:171
    Download:12
    Times Cited: 0

    A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma rat sarcoma viral oncogene homolog (NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type, proficient mismatch repair (pMMR), in whom a complete response to the third-line of systemic treatment with trifluridine/tipiracil (TAS-102) was obtained. The complete response has been maintained for more than 2 years after its suspension.

    • Submit a Manuscript
    • Aims and Scope
    • Editorial Board
    • Author Instructions
    • Ongoing Special Issues
      Off-Label Drugs and -Omics Data in Cancer Treatment
      COVID-19 and Cancer
      Antibody-Drug Conjugates
      The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy
      Gene Delivery Approach to Fight Cancer
      The Implementation of Liquid Biopsy in Clinical Practice for Different Solid Tumor
      Cancer Immunotherapy and Tumor Microenvironment
      Theranostic Frontiers in Neuro-Oncology
      Plant Extracts as an Infinite Resource for New Anticancer Agents
      Cancer Stem Cell Targeting Therapy
      Emerging Screening Technologies in Drug Discovery
      Biomarkers for Personalized and Precise Cancer Diagnosis and Treatment
      Artificial Intelligence for Precision Oncology
      Integrated Approaches for Non-Small-Cell Lung Cancer
      Innovative Strategies to Target Triple-negative Breast Cancer
      DNA Damage as Target for Therapeutic Intervention
      Therapeutic Targeting of the Tumor Microenvironment
      Molecular Targeted Therapy for Cancer
      Novel Strategies and Targets for Immunotherapy of Cancer
      Molecular Diagnosis and Personalized Therapy of Cancer
      Recent Approaches in Tumor Metabolism
      Novel Insights into Immunotherapy Targeting Tumor Microenvironment in Cancer
      Posttranslational Modifications in Health and Disease
    • Completed Special Issues
      Liquid Biopsy in Thoracic Cancer
      Targeting Transcription Factors for Cancer Therapy
      Immunotherapy in Cancer Patients
      Calcium Signaling Apparatus in Cancers
      Proteolysis Targeting Chimera (PROTAC)
      Precision Medicine for Cholangiocarcinoma
      Endocrine Resistant Breast Cancer
    • Guest Editor
    • About the Special Issue
    • Call for Papers
    • Published Articles
    • Exploration of Targeted Anti-tumor Therapy
    • eISSN 2692-3114
    • etatjournal@explorationpub.com
    • About the Journal
    • Author Instructions
    • Editorial Board
    • Editorial Policies
    • Editorial Process
    • Follow the Journal
    • JOURNALS
    • Exploration of Medicine
    • Exploration of Targeted Anti-tumor Therapy
    • Exploration of Immunology
    • Exploration of Neuroprotective Therapy
    • Exploration of Digestive Diseases
    • Exploration of Neuroscience
    • Exploration of Musculoskeletal Diseases
    • Exploration of Asthma & Allergy
    • Exploration of Drug Science
    • Exploration of Foods and Foodomics
    • Exploration of BioMat-X
    • Exploration of Digital Health Technologies
    • Exploration of Cardiology
    • Exploration of Endocrine and Metabolic Disease
    • ABOUT
    • Company Information
    • Open Access
    • Editorial Policies
    • Peer Review Policy
    • Contact Us
    • FOLLOW
    • Terms of Service Privacy Cookies
Copyright © 2023 Open Exploration Publishing Inc.